2 In the REIMAGINE 3 trial, the most commonly reported AEs were GI-related, occurring in 51/90 (57%) participants in the CagriSema 2.4 mg/2.4 mg group, 42/93 (45%) participants in the CagriSema 1 mg/1 mg group, and 21/91 (23%) participants in the placebo group
Common injection sites include the abdomen, thigh, and upper arm
Discuss the risk-benefit ratio with your provider
Proteins (100+ amino acids): Regulated as Biologics, which face the strictest federal oversight and generally cannot be compounded
Regulatory compliance: Confirm the suppliers pharmacy licensure and compounding accreditation status
[DOI] [PMC free article] [PubMed] [Google Scholar] 9.Bukowski K, Kciuk M, Kontek R